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. Nevertheless, prominent driver mutations in, for instance, the BRAF or NRAS gene are established early during melanoma development and are already detectable in benign naevi 2 . Furthermore, analyses of cohorts of matched primary and metastatic melanomas have identified neither driver mutations that are restricted to metastases nor a conclusive hier archic mutation pattern associated with metastatic progression [3] [4] [5] [6] [7] . However, melanoma progression to an invasive state is linked to an increase in copy number alterations 8 . This suggests that changes in gene expres sion and, hence, transcriptional programmes play a role in melanoma progression.
Gene expression analyses of cultured melanoma cells have established the existence of two predominant transcriptional programmes. These programmes are expressed in distinct cell populations, defined as either of 'proliferative' phenotype or 'invasive' phenotype [9] [10] [11] [12] [13] , a terminol ogy that has also been widely adopted when describing cell populations within the tumour tissue. Over the years, the gene expression signatures related to these two phenotypes have been confirmed and expanded (Table 1) . Crucially, the proliferative and invasive phenotypes are not defined by particular genetic lesions, and changes in transcriptional activity can reprogramme a phenotype.
Moreover, the transcriptomes of the invasive and pro liferative phenotype are governed by distinct transcrip tional master regulators [14] [15] [16] . Consequently, depending on the balance between the expression and/or activity of transcriptional master regulators, cells are capable of adaptive phenotype plasticity or 'phenotype switching' . Importantly, the occurrence of phenotype plasticity, reminiscent of the epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) of epithelial cancer cells, has been observed in vivo 17 . Considering that transcriptional changes are induced through signalling pathways activated by extracel lular factors, the tumour microenvironment (TME) plays a major role in adaptive phenotype plasticity. Different non cancer cells in the TME as well as meta bolic conditions such as oxygen and nutrient supply can modify phenotypes and drive them from prolifer ative to invasive, and vice versa 9, [11] [12] [13] . These micro environmental effects can explain the intertumour as well as the intratumour phenotype heterogeneity fre quently observed in melanoma. Indeed, histo logical analyses of melanoma biopsies revealed distinct expres sion of the melanoma tran scriptional master regulator microphthalmia associated transcription factor (MITF), a marker of the proliferative phenotype, and the tyrosine protein kinase receptor AXL, a marker for the invasive 'Proliferative' phenotype Distinct cell population with enhanced proliferation in culture, linked to expression of microphthalmia-associated transcription factor (MITF) and its target genes, which regulate the cell cycle and pigmentation.
Phenotype plasticity as enabler of melanoma progression and therapy resistance Abstract | Malignant melanoma is notorious for its inter-and intratumour heterogeneity , based on transcriptionally distinct melanoma cell phenotypes. It is thought that these distinct phenotypes are plastic in nature and that their transcriptional reprogramming enables heterogeneous tumours both to undergo different stages of melanoma progression and to adjust to drug exposure during treatment. Recent advances in genomic technologies and the rapidly expanding availability of large gene expression datasets have allowed for a refined definition of the gene signatures that characterize these phenotypes and have revealed that phenotype plasticity plays a major role in the resistance to both targeted therapy and immunotherapy. In this Review we discuss the definition of melanoma phenotypes through particular transcriptional states and reveal the prognostic relevance of the related gene expression signatures. We review how the establishment of phenotypes is controlled and which roles phenotype plasticity plays in melanoma development and therapy. Because phenotype plasticity in melanoma bears a great resemblance to epithelial-mesenchymal transition, the lessons learned from melanoma will also benefit our understanding of other cancer types. [19] [20] [21] and has underlined their importance for mela noma, particularly in the context of therapy. Emerging evidence suggests that phenotype plasticity is at the core of the development of resistance not only to tar geted therapy but also to immunotherapy 20, 22 , making phenotype plasticity a major obstacle for the cure of melanoma.
In this Review we discuss how melanoma pheno types are defined through gene expression signatures, examine their prognostic relevance, and describe how the establishment of phenotypes is controlled. Overall, we discuss the role of phenotype plasticity in melanoma progression and therapy response, as well as how key processes in phenotype plasticity could be therapeutic targets used in novel treatment options. (Table 1) . Of note, MITF is the master transcription regulator of the melanocyte lineage, and apart from controlling melanoma cell survival and proliferation, it stimulates differentiation and pigmentation through genes such as EDNRB and MLANA
24
, which are markers of gene expression signatures linked to the proliferative phenotype 23, 25 . Moving on from cell lines, a later study included datasets from melanoma biopsies and applied RNA seq, which allowed significantly expanding the size of the individual gene sets (Table 1) . This study validated and expanded previously defined signatures and identi fied an MITF-SOX10governed proliferative signature that contained 68-99% of the previously defined gene signatures, as well as an activator protein 1 (AP1)-TEA/ATTS domain (TEAD)governed invasive signa ture that contained 65-69% of the previously defined gene signatures 16, 18 . Of note, the signatures do not cor relate with the presence of any known melanoma driver mutation, such as BRAF V600E or NRAS
Q61L
, which suggests that transcriptional reprogramming occurs, leading to gene expression programmes that are disconnected from driver mutations 14, 15 . Analyses of datasets from biopsies also enabled the identification of a gene expression signature that dis tinguishes melanoma from other cancers, and that as such is upregulated specifically in melanoma 26 (Table 1) .
Mapping these genes onto the cell lines of invasive or proliferative phenotypes revealed a proliferative signa ture enriched in genes that promote melanocyte dif ferentiation, which are MITF, its target genes and its upstream regulators SOX10 and PAX3. Intriguingly, the analysis did not identify a single overlap with the 643 genes defining the invasive signature 15 . Because the study aimed to identify a signature containing 'melanoma specific' genes 26 , this suggests that invasive signature genes are not specific for melanoma but might be applicable to more cancer types.
In general, a fairly clear picture of the gene expression landscape in melanoma cells is emerging. The invasive and proliferative phenotype gene signatures describe part of a series of melanoma cell states that relate to different phases of melanocyte lineage development, ranging from neural crest stem cells to differentiated, pigmented melanocytes 20,21 (Table 1) . Nevertheless, when these signatures are 'mapped' onto tumours, the expres sion of genes reflecting the TME -in particular, genes specific to immune cells and associated with a lympho cyte infiltrate -can be identified 15, 19, 27 . Moreover, while bulk sequencing of tumours can identify the dominance of either a proliferative or an invasive phenotype signa ture, single cell analyses revealed that both phenotype signatures can coexist and contribute to intratumour heterogeneity 19, 28 . Such heterogeneity can be seen macro scopically in melanomas that consist of radial and vertical growth components 29, 30 and can explain gene expression signature variations found in individual metastases derived from the same primary tumour 31 .
Phenotype plasticity and cooperativity
The intratumour phenotype heterogeneity found in mela nomas can be a direct result of the adaptive plasticity of melanoma transcriptomes, which enables the fluent con version from one phenotype into another in response to external cues. 17 . This study laid the ground for the so called phenotype switch model, in which adaptive switching between different phenotypes in response to the TME is thought to drive melanoma progression (FIg. 1a) .
The 39 . On the other hand, although the proliferative pheno type requires the transcriptional activity of MITF, the expression of MITF in invasive cells does not neces sarily induce a proliferative phenotype, because it can result in the suppression of melanoma cell proliferation and xenograft growth 39, 40 . It appears that the transition from an invasive to a proliferative phenotype requires additional changes, such as epigenetic modifications, for MITF to drive the transcription of proliferation and differentiation genes. Indeed, the chromatin landscape differs between fully established phenotypes; open chro matin at active enhancers in the proliferative phenotype
Epithelial-mesenchymal transition
(eMT). a non-mutational process that generates epithelial-derived phenotypes, which have lost their cell polarity and gained migratory and invasive properties.
Mesenchymal-epithelial transition
(MeT). The reverse process from epithelial-mesenchymal transition, representing the transition from motile, mesenchymal cells to planar arrays of polarized epithelial cells.
Melanocyte lineage
Neural crest-derived cells that produce the pigment melanin and are located in the basal layer of the epidermis as well as in the eye, inner ear, meninges, heart and bones.
Pigmentation
Deposition of the pigment melanin, which is produced by differentiated melanocytes, in keratinocytes in the skin.
Transition states
Intermediate, hybrid states of stable phenotype states that are characterized by distinct transcriptional and epigenetic landscapes, gene regulatory networks, transcription factors and signalling pathways.
NATuRe RevIeWS | CAnCER overlaps with active enhancers in melanocytes, and open chromatin at active enhancers in the invasive phenotype overlaps with active enhancers in skin fibroblasts 15 . In addition, regions of active and repressed chromatin are correlated with regions of decreased and increased methylation, respectively 15 , and in invasive phenotype cells the MITF promoter as well as the promoters of its target genes are hypermethylated 41 . Consequently, ectopic MITF expression cannot stimulate the expres sion of MITF target genes. Thus, the need for epigenetic modifications might explain why MITF overexpression alone cannot induce a phenotype switch in cell lines with a fully established invasive phenotype.
The question remains why the switch from a pro liferative to an invasive phenotype can be experimen tally achieved, while induction of the reverse switch seems more difficult (Table 2) . Possibly cellular changes (in adhesion receptors, matrix metalloproteinases, etc.) leading to invasive behaviour as measured by com mon in vitro assays can be induced fast, before the full 2) , and that the forced switch from a 'prolifer ative signature' to an 'invasive signature' phenotype might actually be more difficult. Indeed, SOX9 overexpression induces increased invasion in vitro, but this is accompa nied by only a partial enrichment of only 10% of inva sive signature genes 42 . Another example is seen with the nerve growth factor receptor NGFR (also known as CD271), which is expressed in neural crest stem cells 43 and, although the finding is controversial [44] [45] [46] , has been identified as a marker of melanoma initiating cells 47 . NGFR overexpression in melanoma cells can induce transcription linked to an altered matrix adhesion phenotype within 24 hours, but at this time there is no major overlap with the invasive gene signature 48 . Finally, transcription regulators or epigenetic factors such as the EMT regulator ZEB1 (reF.
49
), as well as HOXA1 (reF.
50
) or BMI1 (reF.
51
), can enhance in vitro invasion and increase the expression of genes contained within the invasive signature, but they do not induce a slow cycling pheno type, and their effects on proliferation are inconclusive (box 2). Thus, although all these factors enhance inva sive properties, they are not sufficient to consolidate a slow cycling phenotype. This suggests that for the global reprogramming underlying plasticity between the stable slow cycling, invasive state and the stable proliferative, differentiated state to occur, cells need to integrate vari ous signals over a prolonged period of time; only this will enable a cell to establish an epigenetic state compatible with a stable phenotype (FIg. 1b) . Once a stable pheno type is established, a cell appears to be 'locked' in a tran scriptional state supported by its particular epigenetic landscape. Such a scenario is in line with findings made in cells undergoing EMT, where transition states exist and plasticity is observed, but the epithelial or fully established mesenchymal states are less plastic 52 . The importance of phenotype plasticity for mela noma progression has been elegantly demonstrated with an inducible NGFR system in mice 48 . Prolonged NGFR overexpression induces an invasive phenotype and reduces tumour growth in mice, but the previous state can be recovered after receptor expression is switched off 48 . Most importantly, the reversible NGFR expression that allows for proliferation to recover is essential for efficient metastasis, because when NGFR overexpression is not switched off, metastasis does not occur. Similarly, melanoma cells of the invasive phenotype can only ini tiate metastasis in zebrafish if they undergo an EDN3 induced switch to a proliferative gene programme (Table 1) once they arrive at the metastatic site 12 .
For a cell to disseminate, it has to adopt invasive properties, but the findings described above suggest that its overall transcriptional state can stay transient, allow ing for microenvironment induced adaptive plasticity to occur. This plasticity promotes progression, because as was seen with NGFR, a fully established invasive pheno type alone is insufficient to cause metastatic disease, and a reversible switch to a proliferative phenotype is required for metastasis to develop. Reversibility is key to melanoma progression driven by phenotype plasticity, but whether one direction is favoured over the other will also depend on the particular microenvironment, where, for instance, one state is energetically more stable than the other (FIg. 1b) . Considering the effects of phenotype plasticity and metastatic growth on disease outcomes, it will be crucial to identify which transition represents the bottleneck for the development of metastasis.
Communication between phenotypes leads to cooperativity. The phenotype switch model postulates that during certain steps of the metastatic process, we should encounter only invasive cells (FIg. 1a) . However, the phenotype heterogeneity found not only in individual metastases 19 , but also in circulating melanoma cells 53, 54 , challenges the simplicity of this model. It seems likely that in a heterogeneous situation, communication between cells of different phenotypes occurs. This can result, for example, in cooperative actions that overall further the metastatic process while maintaining hetero geneity (FIg. 1c) . In epithelial cancers, there is growing evidence that cooperativity can occur and can contrib ute to collective migration, efficient dissemination, pre metastatic niche conditioning and the initiation of metastasis 55 . Notably, melanoma cells also cooperate, and the communication between cells of the invasive phenotype and cells of the proliferative phenotype can increase the overall efficiency of invasion in vivo 56 . In this regard, heterogeneous MITF expression has also been detected in circulating melanoma cell clusters 53 . Cells in circulation are challenged by cell death induced by detachment (anoikis), and MITF low invasive pheno type melanoma cells expressing the AP1 transcription factor subunit FOSL1 are resistant to anoikis 57 . Thus, MITF high cells, which are otherwise prone to anoikis, ; the transition states reflect sequential dedifferentiation and differentiation between the stable phenotypes. A threshold must be overcome in order to transit between stable states, but the energy level of the stable states, and hence the threshold, might differ for the individual phenotypes. Different transcriptional master regulators are active on either side of the threshold. Microphthalmia-associated transcription factor (MITF) downstream of, for instance, MCR1, endothelin receptor type B (EDNRB) or BRAF/MAPK signalling controls differentiation and proliferation 24 . Activator protein 1 factors (FRA1, JUN) -which are upregulated, for instance, by MAPK pathway hyperactivation 122 , or possibly through TNF 38 -suppress MITF and stimulate dedifferentiation. WNT5A and transforming growth factor β (TGFβ) activate TEA/ATTS domains (TEADs) and small mothers against decapentaplegic proteins (SMADs), respectively , which together can drive further dedifferentiation and establish a slow-cycling phenotype 144, 145 . Of note, this model assumes that MITF-expressing cells also possess invasive potential, possibly when pigmentation levels are low 33 . c | Reciprocal interaction between the different phenotypes results in cooperativity and the maintenance of heterogeneity during melanoma progression. Phenotype plasticity occurs, but it is not strictly required at all times. Parts a and c are adapted from reF.
56
, CC-BY-3.0 (https://creativecommons.org/ licenses/by/3.0/). might receive a survival benefit from attachment to MITF low cells within circulating clusters. This explains why proliferative phenotype genes are present in a 19gene signature that specifies circulating melanoma cells in patients 58 .
Overall, although phenotype plasticity occurs, it can not be dismissed that phenotype heterogeneity contrib utes to adaptation in cellular function beyond defined phenotypes.
Biological and prognostic relevance Particular functions such as proliferation or invasion have been assigned to cells with distinct phenotype signatures, and this is most clearly represented in the phenotype switch model (FIg. 1a) . However, several findings suggest that cells with an invasive phenotype signature have other properties besides being invasive. Furthermore, the invasive phenotype is frequently referred to as the 'metastatic' and 'more aggressive' pheno type. Nevertheless, while independent approaches to isolate melanoma classifiers with prognostic relevance have identified gene expression signatures that overlap with the invasive and proliferative phenotype signa tures (Table 1) , these studies have consistently found that the proliferative phenotype signature is the one that correlates with poor survival.
Phenotype-specific functions and melanoma development. The definition of the invasive and proliferative phenotypes is based on distinct cell behaviour that was originally assessed in particular in vitro and in vivo assays (box 2), but in the context of melanoma development, phenotype function appears to be less clear cut.
The gene expression signature of the classic inva sive phenotype is void of any MITF transcripts 14, 59 , yet depending on the context, MITF can also stimulate inva sion [60] [61] [62] . Moreover, MITF significantly upregulates 27% invasive signature genes 63 , many of which encode extra cellular matrix (ECM) proteins and matrix remodellers. This makes sense, considering that MITF expression is induced in neural-crest derivatives when the melanocyte lineage evolves as a highly motile cell population 64 . In fact, even adult melanocytes, which are defined by ample MITF expression, are highly motile. This trait is thought to underlie the formation of so called naevus cell aggre gates, small deposits of melanocytes found in the lymph nodes of patients and therefore named 'benign meta stases' 65, 66 . Presumably, when melanocytes encounter rele vant external cues, they are able to migrate and invade without the need to transform. Thus, the ability to disseminate might be an inherent trait of melanocytic cells and not an acquired feature of melanoma pro gression 8 . Following on from this, invasive phenotype cells may be defined by an increase in in vitro invasive capacities, but other properties also seem to be linked to this dedifferentiated phenotype, such as slow cycling or dormancy, altered adhesion signalling and anoikis resistance in addition to drug resistance; these attributes are of major relevance to progression and metastasis 67 as well as to therapy 20, 21, 68 , and we still do not know enough about them.
The proliferative phenotype has probably maintained most of the traits of a melanocyte, in which both the MAPK pathway and MITF drive proliferation 24, 69, 70 . In patients, metastases have the highest mitotic index of all melanoma stages 71 , emphasizing the importance of proliferation. Indeed, induction of the proliferative programme at the metastatic site is a prerequisite for metastasis formation in fish 12 , and MITF expression is required for metastatic outgrowth in mice 72 . To fully comprehend the role of the proliferative phenotype and MITF expression in melanoma, we need to better understand their involvement in instigating prolifer ation in invasive phenotype or dormant cells and their contribution to survival at secondary sites.
Prognostic value of melanoma phenotype signatures.
The quest for identifying melanoma classifying gene expression signatures is driven by the need for appro priate predictors of melanoma. One of the first attempts
Neural-crest derivatives
Diverse cell lineages derived from neural-crest cells, which include melanocytes, craniofacial cartilage and bone, smooth muscle, peripheral and enteric neurons and glial cells. Numerous studies have demonstrated that primary and secondary melanomas display high similarities in genetic makeup as well as gene expression patterns [4] [5] [6] 8, 73 . This fact strongly argues against a role for clonal evolution and expansion of the fittest clone after competitive selection as a major driver of melanoma progression 138 . Nevertheless, an alternative concept that is discussed involves cancer stem cells (CSCs), which are transformed cells with normal stem cell characteristics that are thought to drive unlimited tumour growth in a hierarchical fashion 138 . This concept is accepted for various cancer types, but the relevance of CSCs for melanoma progression has been a matter of debate for some time. While melanoma cell subpopulations that display characteristics of stemness, such as extensive self-renewal or single-cell tumour initiation, have frequently been identified, inconsistencies in verifying established markers of CSCs have undermined efforts to confirm their existence 44, 139, 140 . The concept of CSCs in melanoma has also been challenged on the basis of the theory's postulation that only rare subpopulations of cells within a tumour have the capacity to initiate and sustain tumour growth, because it was demonstrated that in 28% of cases single melanoma cells directly isolated from patients could initiate tumours and were capable of indefinite growth 46 . In addition, the aforementioned study showed that the phenotypic heterogeneity observed in initial xenografts was maintained after injection of individual marker-fractionated cell populations. Together, these findings not only suggest that tumour-initiating cells are rather common in melanoma, but also support the concept of non-hierarchical plasticity. It has been suggested that such plasticity could lead to the transient existence of slow-cycling cells with stem cell properties 141 , which has been named 'dynamic stemness'. Such a concept is supported by the existence of melanoma cell subpopulations that possess neural-crest features and are dedifferentiated further than the classic invasive phenotype (neural-crest stem cell (NCSC), Table 1 ), but most importantly, that show dynamic behaviour 20, 21 . Thus, though they are perceived as difficult to define, melanoma CSCs could in fact be plastic neural-crest stem cell-like cells that contribute to melanoma growth and progression as well as to therapy resistance.
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identified genes related to cell cycle progression and proliferation as being significantly upregulated in pri mary melanomas of patients who developed metastasis within the next 4 years following diagnosis 73 (Table 1) .
Remarkably similar correlations of poor patient survival with the expression of proliferation and/or cell cycle genes were seen with several other melanoma cohorts, including the TCGA panel of primary and metastatic melanomas 27, 71, 74, 75 (Table 1 ). In line with this, the mitotic index of melanomas appears to be the strongest predic tor of poor outcome 71 . On the other hand, a gene expres sion signature related to immune response is correlated with better survival 27, 71, 74, 75 . MITF and its target genes regulating the cell cycle, including CDK2 and BRCA1, as well as target genes regu lating pigmentation, are expressed in tumour biopsies of the poor survival patient groups, which is in line with the classic proliferative gene signature 71, 74, 75 (Table 1 ).
The expression of pigmentation genes is in line with the fact that the expression of melanocyte differentiation genes per se is also correlated with poor survival 26, 76 . Although at first glance this might appear contradic tory, the processes of proliferation and differentiation in melanocytic cells are not mutually exclusive, because MITF has a dual role in controlling the genes involved in proliferation and differentiation, as we mentioned above. In fact, cell division of pigmented -that is, differentiated -melanocytes occurs and has been monitored by live imaging 77 . Another interesting observation is that although the best survival correlates with the immune response group, this signature displays low expression of MITF and its target genes 74 , suggesting a possible phenotype specific interplay with the immune microenvironment. Indeed, single cell RNA seq of human melanoma biop sies have revealed that T cell infiltration is correlated with complement factors expressed by cancer associated fibroblasts (CAFs) and that CAF rich tumours express an AXL high signature, whereas expression of an MITF high programme in melanoma cells is negatively correlated with CAF abundance, and hence with T cell infiltra tion
19
. Thus, apart from the cellular functions assigned to distinct phenotypes, the phenotype induced TME affects melanoma progression, and the interplay of mela noma cells with the TME might contribute to the poor prognosis seen in patients with tumours of a proliferative phenotype signature.
Multiple factors control phenotypes
Whereas certain traits of melanoma cells are inher ent to the melanocytic lineage, locally distinct factors in the TME affect melanoma phenotypes and con tribute to pheno type heterogeneity (FIg. 2) . Likewise, melanoma cells of distinct phenotypes can shape the melanoma micro environment, because the effect of intercellular communication based on cell-cell interactions and secreted factors is phenotype dependent.
Resident cells in the TME control melanoma phenotypes. Within a tumour there is a constant flow of communications between cancer cells and other cell types in the microenvironment; these communications are reciprocal and contribute to the establishment of certain phenotypes. Major contributors to these inter actions are CAFs 78 (FIg. 2a) . Indeed, co culture of mela noma cells with CAFs leads to induction of an invasive MITF low -AXL high phenotype in melanoma cells 79 , and this phenotype is enriched in melanomas with high CAF abundance 19 . Ageing CAFs become more likely to induce an invasive AXL high phenotype in melanoma cells 80 , and this induction is further facilitated by reduced secretion of ECM components and remodellers such as hyaluro nan and proteoglycan link protein 1 (HPLN1), which lowers matrix stiffness to favour invasive behaviour 81 . But the interplay between the ECM, CAFs and melanoma cells is complex. Whereas in tumours with low relative amounts of CAFs, collagen abundance -and there fore ECM stiffness -triggers differentiation and an MITF high phenotype, the abundance of CAFs can over come this effect, because CAF derived TGFβ stimu lates dedifferentiation 76 (FIg. 2a) . Mechanistically, ECM stiffness drives MITF expression through a YAP-PAX3 complex, but the presence of TGFβ stimulates recruit ment of YAP to TEAD, which suppresses MITF expres sion. Thereby, YAP acts as a crucial rheostat between MITF driven and TEAD driven transcriptional states 76 . The relevance of the ECM in the TME can be seen in patient survival data, where the worst prognoses are seen in patients with melanoma in which high collagen MITF, microphthalmia-associated transcription factor ; NGFR , nerve growth factor receptor ; TGFβ, transforming growth factor β; TNF, tumour necrosis factor.
NATuRe RevIeWS | CAnCER expression is paired with the expression of MITF target genes 76 . What has not been considered yet is the factor of age, because not only do ageing fibroblasts contribute to a change in ECM composition, but the structure of matrix proteins such as collagen also changes through the accumulation of ultraviolet (UV) damage over time 82 . Nevertheless, acute UV irradiation affects melanoma progression as well, not only by causing DNA damage in melanocytes, but also through an inflammation mediated switch to a dedifferentiated state. This switch produces a motile phenotype that is prone to metastatic spread along blood vessels (angiotropism) 37 (FIg. 2b) .
Curiously, the melanoma cells detected along these blood vessels display pigmentation and expression of the differentiation markers TRP1 and S100. This exem plifies the transient nature of the switch and suggests that once the cells are located along the vessels and local inflammation has subsided, the cells can switch back to a state of differentiation and continue to migrate.
Central to inflammation mediated phenotype plas ticity is the pro inflammatory cytokine TNF (Table 2) , which is produced by neutrophils, activated T cells and myeloid cells. TNF suppresses MITF and induces the expression of JUN, a subunit of the transcription fac tor AP1 (see FIg. 1b ), leading to a pro inflammatory MITF low -JUN high state 38 . However, MITF binds to and blocks the JUN promoter, and in cells expressing high MITF levels, TNF is not able to induce JUN and thus is inefficient in inducing a switch to the JUN high pheno type. Moreover, when the MAPK pathway upstream of JUN is inhibited, TNF induces MITF expression through transcription factor TF65 (also known as RELA), which binds to the MITF promoter 83 . It appears, therefore, that not all melanoma cells respond to TNF equally. Rather, cells need to be primed for the pro inflammatory action of TNF, and this priming is related to the abil ity of TNF to upregulate JUN expression. Once estab lished, the MITF low -JUN high state displays inflammatory hyperresponsiveness, which in mice promotes a mye loid cell enriched TME 38 (FIg. 2b) . In a mouse model for adoptive cell transfer therapy (ACT), TNF induced phenotype plasticity enables melanoma cells to escape cytotoxic T cells, which contributes to therapy resist ance 13 . A similar escape is seen when melanoma cells are co cultured with natural killer cells, which induce a mesenchymal phenotype in melanoma cells 84 . These observations could suggest that switching to an MITF low phenotype is correlated with escaping an immune response. However, while exposure to TNF resulted in escape from melanocyte differentiation antigen (MDA) specific T cells, the recognition of melanoma cells by T cells specific for non melanocytic antigens appeared to be unaffected, or even to increase 13 . In line with this, downregulation of MITF in human melanoma cells in vitro results in increased cytokine release and immune cell attraction 85, 86 . Furthermore, in patients with mela noma, an immune response signature correlated with increased lymphocyte infiltration and better survival was found to be related to an MITF low state and the absence of proliferative markers 71, 74 . Thus, the MITF low state might be more immunogenic or is connected to a microenvi ronment that effectively recruits immune cells, as was seen in CAF rich AXL high signature melanomas with higher T cell infiltration 19 .
Control through physiological conditions in the TME.
The presence of different resident cells and other fac tors within the TME also influences the availability of oxygen or nutrients (FIg. 2a) , which in turn contributes to the adaptation of melanoma phenotypes to optimize survival and growth. At sites of non functional blood vessels, low levels of oxygen (hypoxia) directly affect cells of the TME, including melanoma cells. In parti cular, hypoxia promotes a dedifferentiated phenotype in mel anoma cells, which has lower oxygen consumption and is therefore more likely to survive 87 . A further driving force for a switch to a dedifferentiated phenotype could be that this phenotype is capable of vasculogenic mimicry and, as such, can contribute to neovascularization [88] [89] [90] . Mechanistically, the switch is linked to MITF suppres sion mediated by the hypoxia induced transcription factor HIF1α, which stimulates expression of the tran scriptional repressor BHE40, which in turn binds and suppresses the MITF promoter and hence promotes dedifferentiation 9, 59, 91, 92 (Table 2) . Under normoxic conditions, MITF induces the expression of PRGC1, a transcriptional co activator that promotes mitochon drial energy metabolism and reactive oxygen species (ROS) detoxification 87 . However, in hypoxic cells, when MITF is suppressed, the cells are more glycolytic and ROS levels are elevated, and hence, these dedifferenti ated cells are exposed to oxidative stress. Importantly, 
Adoptive cell transfer therapy
(aCT). a type of immunotherapy in which T cells, usually taken from a cancer patient's own blood or tumour tissue, are propagated in vitro and given back to a patient so as to target the tumour(s). 
Melanocyte differentiation antigen

Vasculogenic mimicry
ability of metastatic tumour cells to mimic a true vascular endothelium and form microvascular channels without the presence of endothelial cells.
Box 2 | Assessing the function of the invasive and proliferative phenotypes
Bittner and co-workers 23 were the first to link a particular gene signature to invasive behaviour, which they measured as matrigel invasion towards fetal calf serum (FCS), a standard assay still used to define this phenotype. Thereby, invasion depends on FCS-responsive receptors, which are highly expressed in invasive signature cells (for example, eGFR, PDGFR, and AXl). Thus, proliferative signature cells may not respond to FCS as chemo-attractant, yet they exhibit invasive activities. Indeed, cell lines defined as proliferative can display higher basal matrigel invasion than invasive lines 15 , and they can use other chemo-attractants, such as endothelin 1 (eDN1) or eDN3 (reF.
142
). Furthermore, the proliferative phenotype is considered 'non-metastatic'. However, depending on the immune background in mice, proliferative phenotype cells can be highly metastatic 94 -even more metastatic than invasive signature cells (C.W. and I.A., unpublished observations) -suggesting that the immunogenicity of individual phenotypes in mice affects their 'metastatic' potential.
Correlating the proliferative signature to proliferation in vitro has been inconclusive [15] [16] [17] 26, 51 , but the first study evaluating phenotypes in vivo found that proliferative phenotype cell lines produced rapidly growing tumours within 10 days, whereas tumour growth for invasive signature cell lines occurred 30 days later and was slow 17 . This is intriguing, as the efficiency to grow a tumour is considered a feature of tumorigenic potential that is also linked to dedifferentiated tumour-initiating cells, and indeed, other studies have shown that only cell lines of invasive phenotype grow tumours, and proliferative phenotype cells do not 26, 49, 50, 143 . Furthermore, inducers of an invasive phenotype, such as BmI1, HoXA1 or ZeB1, should reduce proliferation, but while BmI1 has no effect 51 , HoXA1 actually accelerates tumour growth 50 and depletion of ZeB1 results in no tumour growth at all 49 . overall, there seems to be no consensus on how to confirm melanoma phenotypes with regard to 'proliferation', which poses a problem for interpreting a phenotype switch, particularly in vivo.
on the basis of phenotypes' gene expression profiles, it is possible to assign particular functions to phenotypes. However, with a stark focus on invasive behaviour and the lack of any agreed-upon standard for how and when to assess proliferative behaviour in vivo, we might be missing important features of these phenotypes that have major importance for melanoma progression.
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HIF1α in its role in oxygen availabilityrelated stress signalling has also been linked to counteracting ROS production 93 . HIF1α could therefore protect cells of the MITF low dedifferentiated phenotype from elevated ROS levels. Intriguingly, ROS levels are also increased when aged fibroblasts induce a switch to a dedifferenti ated phenotype 80 , but a potential role for HIF1α in this scenario is not known.
Because the rate of oxygen consumption is directly linked to intracellular production of energy from nutrients, nutrient availability is also a crucial factor in regulating melanoma cell phenotypes. For instance, glucose restriction leads to reduction in glycolytic flux and to ROS accumulation, which via ATF4 induces transcriptional repression of MITF and a switch to an MITF low -AXL high phenotype 11 that is inefficient at oxida tive phosphorylation 11, 87 . Restriction of the amino acid glutamine also leads to the establishment of an MITF low -AXL high phenotype, whereby the repression of MITF expression and the repression of pro invasive activities are mediated by transcriptional and trans lational events 10 . Overall, it seems that oxygen and nutrient limitation leads to adopting a slow cycling phenotype, which is more likely to survive the harsh metabolic conditions in the TME. Of note, melanoma cells expressing a 'nutrient deprived cells' signature also express high levels of the fatty acid transporter CD36 (reF.
20
), suggesting that they are primed to increased fatty acid uptake. CD36 labels slow cycling, undifferentiated carcinoma cells, and in animal models CD36 regulates the metastatic capacity of several cancer types, includ ing melanoma 94 . Thus, fatty acids might fuel melanoma progression, but so far, nothing is known about the role of CD36 and fatty acid metabolism in slow cycling melanoma cells.
Phenotype plasticity during therapy MAPK inhibitors (MAPKis) effectively block prolif eration in BRAF mutated MITF high melanomas, but most patients eventually progress 95, 96 . Although therapy resistance based on acquired mutations is partially to blame for this 97 , mounting evidence points to a parallel process, in which the plasticity of melanoma transcrip tomes allows for adaptation of cells to the presence of the drug and for drug resistance 98 . Immune checkpoint inhibitors can produce durable responses in ~16-40% of patients with a follow up up to 10 years [99] [100] [101] , yet up to 30% of patients who respond for a period of time relapse on the treatment 95, 102 . Phenotype plasticity also plays a role here, because individual phenotypes differ in their immunogenicity and their interaction with the immune microenvironment 103, 104 .
Phenotype plasticity drives resistance to targeted therapy. It is now well established that melanomas adapt when they are challenged by MAPKis, and studies in cultured cells have revealed that during this adapta tion transcriptionally distinct cell populations emerge over time, with an initial phase of populations show ing increased melanocytic differentiation (MITF high ), 35, 92 . Glucose and glutamine restriction induce an MITF low -AXL high phenotype by downregulating MITF through ATF4 (reFS 10, 11 ). Importantly , the hypoxia-induced as well as glucose or glutamine restriction-induced switch leads to MAPK inhibitor therapy resistance 10, 92, 118 . b | Immune cells are the source of numerous secreted factors that control cellular behaviour and have a major impact on melanoma cell phenotype plasticity. Ultraviolet irradiation triggers the recruitment of neutrophils, which induce inflammation and, through tumour necrosis factor (TNF), stimulate angiotropism, whereby extravascular migration of pigmented differentiated cells can be seen (Table 1) . Crucially, in patients with melanoma under going treatment with BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi), the respective transcriptional states in the tumour can coexist at the initial drug response phase, although there is clear interpatient variability with regard to predominant states 20 (FIg. 3a) .
In the initial response phase, up to 78% of melano mas of patients on treatment with MAPKi display an increase in MITF high cells 20,108 (FIg. 3a) , which can result in a drug tolerant state, because MITF mediated sur vival signalling can counteract MAPKi induced cell death 108, 109 . In parallel, cell populations expressing an invasive as well as a neural crest stem cell like signa ture increase in number and often co emerge within the same tumour 20 (FIg. 3a) . These cell states correlate with the enrichment of a repertoire of receptor tyrosine kinases (RTKs) such as NGFR 20 113, 114 . This might explain why, at the relapsed stage, ~70% of melanomas show increased expression of the most prominent resistance marker AXL 115 (FIg. 3a) , resulting in an overall trend towards an AXL driven transcriptional programme in these resist ant tumours 19 . Accordingly, MITF expression is reduced in ~50% of relapsed melanomas 108 . Nevertheless, ~23% of melanomas relapse with upregulated MITF expres sion 108 (FIg. 3a) , which, apart from transcriptional plas ticity, can be based on MITF gene amplifications, an event correlated with disease progression 116, 117 . Gene expression analysis can identify changes in indi vidual transcriptional states in tumours on treatment, but in vitro single cell analyses were required in order to demonstrate that these states are based on transcrip tional reprogramming rather than on selection. These analyses identified the existence of individual cells that co express increased levels of several resistance markers, such as EGFR, AXL or NGFR 21, [105] [106] [107] . These cells appear to be primed for resistance, and BRAFi treatment leads to further upregulation of these markers and to a tran sient, reversible resistance. In line with what is observed in patients, these changes are paralleled by the loss of SOX10 and increases in TEAD and AP1 expression 106 . As we mentioned above, exposure to MAPKi can enrich tumours in dedifferentiated, slow cycling, drug tolerant melanoma cell populations, and these popula tions display chromatin modifications and upregulation of histone demethylases 21, 68, 118, 119 . Dedifferentiation appears to be a frequent response to MAPKis, which would allow these slow cycling melanoma cells to per sist until the acquisition of mutations leads to established resistance 120 . In vitro studies suggest that the dediffer entiated state can be transient, but it has also been shown that prolonged BRAFi incubation can stabilize this state 21, 106, 107 , presumably through epigenetic reprogram ming, as seen in tumours from patients with acquired resistance 121 . A stabilization of MAPKi induced resist ance is seen in drug addicted melanoma cells, in which removal of the drug results in cell death, presumably because the cells are unable to adjust quickly enough to switch back to alternate survival signalling 122 . Predicting the reversibility of MAPKi resistance is crucial when considering therapy strategies involving drug holidays and drug rechallenge.
Intercell communication contributes to resistance.
Despite the obvious complexity provided by tumour heterogeneity, we know surprisingly little about how communication between cells of different phenotypes influences the responses to targeted therapy. In fact, the MAPK pathway regulates the expression of numerous secreted proteins, and MAPKis profoundly alter the composition of these secretomes 123, 124 , which in turn stimulates novel cell-cell interactions (FIg. 3a) . Within a heterogeneous tumour, this can lead to the nurturing of stably resistant clones 123 , but it can also provide vital growth signals to slow cycling phenotypes 124 (FIg. 3b) . In tumours where MITF upregulation dominates, this initiates MITF-mediated drug tolerance 108, 120 . Further into the treatment, adaptive transcriptional reprogramming and cell-cell communications via the drug-induced secreted factor EDN1 (reF. (FIg. 3a,b) .
Phenotype plasticity affects immunotherapy. Several genetic events have been linked to innate resistance to immunotherapy 102 , but tumours from patients who do not respond to anti programmed cell death 1 (PD1) therapy are also enriched in a mesenchymal transition related transcriptome termed the innate anti PD1 resist ance signature (IPRES) 22 . The IPRES displays similarities to MAPKi resistance signatures, including the expres sion of AXL, ROR2 and WNT5A, which hints at a shared concept of non genomic resistance. In line with this, in a mouse model for ACT, where resistance is based on a lack of T cell recognition due to the absence of MDAs, transcriptional states of progressive dedifferentiation are observed 13, 21 . Ultimately, the transcriptional changes underlying IPRES may be stabilized through epigenetic changes 15, 41 . Indeed, the use of demethylation or histone deacetylase (HDAC) inhibitors has been demonstrated to improve immunotherapy by reactivating the expres sion of immune related genes and tumour antigens 125 . Thus, by means overall similar to the way melanoma cells escape from targeted therapy, melanoma cells seem to be able to escape immunotherapy through transcrip tional plasticity, with a trend towards a mesenchymal phenotype and dedifferentiation.
The link between melanoma dedifferentiation and therapy escape is not always as clear. For example, desmo plastic melanoma typically presents as a fibrotic tumour of invasive cells displaying reduced pigmenta tion, increased expression of ECM and neurotrophic factors, and frequent amplifications of RTK genes 126, 127 , which are characteristics of the dedifferentiated mes enchymal phenotype. However, this melanoma vari ant has a very high mutational burden, which makes it highly immunogenic, resulting in a favourable response to immune checkpoint blockade 128 . Thus, in the con text of an increased mutational burden and immune response, it seems that transcriptional states linked to a loss of MDA expression can be counterbalanced by the mutational burden resulting in neo antigens.
Furthermore, the genetic background of the mela noma may also affect its interaction with the immune system. This is not only seen with different oncogenic drivers in various mouse models 13, 103, 104 , but also rep resented in patients. For instance, in tumour biopsies from patients with melanoma, β catenin mutations and increased canonical WNT signalling, which is linked to melanocyte differentiation, was found to correlate with T cell exclusion 103 . This finding was corroborated in Braf V600E -Pten −/− mice, in which mutant β catenin expressing melanomas displayed increased MDA expres sion, yet T cells were excluded due to the lack of a subset of dendritic cells 103 . Moreover, these differenti ated melanomas did not respond effectively to immune checkpoint therapy. In contrast, in an H-Ras
−/− driven mouse model, depigmented melanomas that have switched to the mesenchymal phenotype recruit T cells but stimulate apoptosis in these cells through recruitment of polymorphonuclear myeloid derived suppressor cells 104 . Overall, these highly dedifferentiated melanomas are resistant to both immune checkpoint therapy and ACT.
Responses to immunotherapy can be durable, but with an increasing number of patients receiving this treatment, it is becoming clearer that acquired resistance poses a problem. The advantage of immunotherapy is the capacity of immune cells to memorize. However, numerous distinct populations of immune cells and complex cell-cell communications are involved in an effective immune response, which makes it difficult to pinpoint one or two simple mechanisms responsible for resistance 102 . Research into immunotherapy resistance is still in its early days, but it is conceivable that apart from the inherent immune background of the host and the mutational burden and driver mutations of the tumour, phenotype plasticity will also affect the outcome of immunotherapy.
Therapeutic opportunities based on targeting phenotypes. A major take home message from our under standing of the concept of phenotype plasticity is that responses to MAPKi in melanoma can be reversible. This means that if at the time of relapse tumours have not accumulated genetic changes that drive resistance, taking advantage of this reversibility is a realistic oppor tunity. Indeed, the success of the concept of drug holi days has been experimentally demonstrated 129 , and emerging evidence suggests that rechallenging patients with MAPKi after relapse can be successful 130, 131 . Moreover, on the basis of our knowledge of the mela noma phenotype dynamics occurring in response to MAPKi therapy (FIg. 3a) , strategies can be envisaged that will monitor markers of the individual transcriptional states during treatment, followed by adjusting treatment with appropriate drug combinations. For instance, in the first weeks of MAPKi treatment, an MITF high state is seen in various patients 20, 108, 120, 132 , which can be overcome by blocking MITF upregulation using nelfinavir 108 or by targeting MITF mediated survival signals and metabolic adaptation 109, 133, 134 . Monitoring the slow cycling AXL high population on treatment has confirmed this population's enrichment at the time of relapse 19, 124 . Approaches to target this pheno type can take advantage of its ROS high state by using ROS or lipid peroxide mediated ferroptosis inducing drugs 21, 87 . Besides, although originally assigned to the proliferative signature 15 , reanalysis identified the nuclear retinoid acid receptor RXRG as driver of the slow cycling neural crest stem cell like population, and co targeting RXR delays the onset of MAPKi resistance 20 . More directly, the AXL specific antibody AXL107 MMAE cooperates with MAPKi to eradicate this resistant population 115 . Considering all these specific approaches, certainly an optimal approach would target both the MITF high and AXL high populations simult aneously, which would require a target that displays phenotype specific expression yet exhibits equal functionality in both pheno types. This condition is fulfilled with the EDN1 receptors EDNRB and EDNRA, which are expressed in MITF high and AXL high cells, respectively (FIg. 3b) . Consequently, blocking EDNR signalling not only profoundly extends the time of BRAFi response but also effectively suppresses the enrichment of AXL high inhibitor resistant cells 124 . 
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Today, treatment options often include both MAPKi and immunotherapy. Combinations of these approaches are currently being explored, and apart from challenging toxicities, responses have varied greatly 135 . In this context the interplay of melanoma phenotypes plays an important role; for instance, upregulation of an MITF high pheno type on BRAFi therapy is correlated with improved T cell recognition 136 , whereas WNT5A reprogrammes local dendritic cells to induce immune tolerance 137 . It will be important to establish whether phenotype plasticity and reversibility play a role, as this might inform as to how one treatment regime can set the scene for the other treatment, and whether acquired resistant tumours from one treatment will still respond to the other.
Great focus has been placed on revealing the phenotypespecific changes related to resistance to ther apy, to improve responses. However, other aspects to phenotype plasticity could be targeted. For instance, sta ble slow cycling cells are not sufficient to cause metastatic disease, because this requires a switch to proliferation. However, we know very little about how proliferation is initiated in a slow cycling, possibly dormant cell. These cells must rely on phenotype specific survival mecha nisms, but while the mechanism by which MITF medi ates survival signalling in MITF high cells has been well explored, what provides survival signals in the slow cycling phenotype has not been established. Moreover, in a heterogeneous tumour, different phenotypes and their transition states coexist, and we have just begun to touch on the complexity of interactions that occur as a conse quence of phenotype heterogeneity. Considering that such communications also promote cooperativity during therapy, isolating the players involved in these interactions should help identify potent therapeutic targets.
Conclusions and perspectives
Phenotype plasticity is central to melanoma initiation, progression and resistance to therapy. Since the first definition of two distinct melanoma phenotypes, it has emerged that identifiable melanoma cell state signatures relate to different development phases of the melano cyte lineage. Hence phenotypes, rather than being only invasive or proliferative, are more complex and describe a melanocyte differentiation gradient. Accordingly, iden tifying invasiveness or proliferation in terms of function in melanoma cells appears not to necessarily correspond to a phenotype defined by gene signature. Furthermore, while MITF induces differentiation, studies analys ing the dedifferentiated and invasive phenotype so far have only focused on the act of MITF suppression in the process of generating this phenotype. Apart from this function, we are only beginning to understand the dynamic changes in chromatin states that underlie phenotype plasticity.
In summary, there is a need to revisit the original 'invasive' and 'proliferative' phenotype definitions and to further investigate the factors that take over in the absence of MITF -possibly AP1, TEADs and small mothers against decapentaplegic proteins (SMADs). We have to improve our knowledge about the dynamics of the epigenetic landscapes and their related gene regu latory networks that drive transition states or stabilize phenotypes. Most importantly, we need to better under stand how phenotypes affect the TME composition, and likewise how the TME controls phenotypes, as this has major implications for therapeutic approaches. Finally, for prognostic purposes, agreement is urgently required on a signature taxonomy that will define 'master signa tures' and their associations with the parameters of mela noma pathology. The use of such master signatures can improve diagnosis as well as the monitoring of therapy response. Moreover, the functional analysis of such sig natures, particularly in the context of the TME, can lead to the identification of targetable master regulators and novel means to target plasticity to improve the current treatment strategies. 
